Chemomab Therapeutics Announces $10 Million Private Placement
July 25, 2024 07:38 ET
|
Chemomab Therapeutics
Chemomab announced a $10 million PIPE that enables the company to extend its cash runway until early 2026, well past 2 upcoming milestones in early 2025.
Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis
July 25, 2024 07:00 ET
|
Chemomab Therapeutics
Chemomab reported positive topline results from Ph 2 trial assessing CM-101 in PSC. Achieved safety endpoint and improved wide range of secondary endpoints
Chemomab Therapeutics Announces New Publications Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis
June 18, 2024 07:00 ET
|
Chemomab Therapeutics
New publication confirms the role of CCL24 in primary sclerosing cholangitis and the potential of CM-101 to impact PSC disease progression and severity.
Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference
June 06, 2024 07:00 ET
|
Chemomab Therapeutics
Chemomab presents new data supporting clinical potential of CM-101 as novel treatment for PSC at EASL 2024 and Gordon Research Conference
Chemomab Therapeutics to Participate in Upcoming Scientific Conferences
May 17, 2024 07:00 ET
|
Chemomab Therapeutics
TEL AVIV, Israel, May 17, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for...
Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
May 09, 2024 07:00 ET
|
Chemomab Therapeutics
Chemomab reported on major progress in Q1 2024, including that it is on track to report Phase 2 PSC topline data at midyear 2024
Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
May 08, 2024 07:00 ET
|
Chemomab Therapeutics
Chemomab has been granted another 180-day extension to regain compliance with the minimum bid price requirement in order to remain listed on Nasdaq.
Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference
May 02, 2024 07:00 ET
|
Chemomab Therapeutics
Chemomab CEO Adi Mor will present at the Aegis Virtual Conference on May 7 at 9:00am ET
Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update
April 24, 2024 07:00 ET
|
Chemomab Therapeutics
Chemomab will release its first quarter 2024 financial results and provide a corporate update on May 9, 2024.
Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis
April 18, 2024 07:00 ET
|
Chemomab Therapeutics
Peer-reviewed patient study validates Chemomab's CCL24 as a novel target linked to greater disease severity and higher mortality in systemic sclerosis